Optimal assessment share structured of Pharmacoeconomics for medical drugs according to minimax criterion

Objective: To develop a comprehensive methodology for the optimal assessment of the share of the use of medicines, based on the procedure for ranking drugs according to the pharmacoeconomic point scale and the minimax criterion was applied. Methods: The author’s approach is based on the minimax principle and allows solving the problem of optimizing the pharma drug portfolio based on available data, without the need to obtain the parameters of the Markowitz model associated with correlation analysis of data. Results: The authors obtained the optimal distribution of medicines in group A, B: 37% to 63%, which the authors consider a promising recommendation for a pharmaceutical company. The use of a similar approach, which does not contradict the Markowitz methodology, but allows us to reasonably accept the parameters of the model and give the optimal solution for the share distribution of drugs in medical practice. Conclusion: These mathematical tools, justified and equipped with an alternative confirmation, the minimax task can and should take a significant place in the complex pharma-analytical methodology of the management of large companies supplying concomitant drugs to the Russian and foreign market. (AU)

Patient Flows, Patient Distribution Computations and Medicines Accounting in the Pharmacoeconomic Models Through Procurement Perspective.

PURPOSE: Stimulating cost reduction of pharmaceutical companies to optimize the structure of distribution of patients by the level of treatment costs in various programs. PATIENTS AND METHODS: In this article, we rise up the issues of pharmacoeconomic modeling related to the description of the patient flows in the pharmacoeconomic model and methods to determining the course dose of drugs under the restriction of integer computations. We established two possible ways of distributing patients through treatment regimens in pharmacoeconomic models, also analyzed the effects of simultaneous and uniform entry of patients into the model. Also, we considered the limitations and possibilities of calculations based on the active substance and packaging, as well as the transition factor of the remainder of the drug in the next time period. RESULTS: A mathematical model of the analysis of the system assessment of patients by the level of risk of abandoning a healthy lifestyle in connection with the growing problems of the difficult-to-control process is developed. The use of a rational data convolution mode allowed us to obtain a criterion for the optimality of the process and a logical point of stability of the pharmaceutical company by rationally applying treatment methods according to established standards (percentage base). This approach makes it possible to influence the management of private clinics through clear ideas on the algorithms for prescribing drugs in each group of patients and their zoning in the vector recovery mode. CONCLUSION: Initial data and sample size: 552 measurements of the intervals of changes in the subject's indicators in seconds (smoothing and scaling the data to the level of the base (analytical) period or the final (barrier) period). Regular use of this approach makes it possible to reserve the resources of the body of a healthy and physically active person in a timely manner for a very reliable functioning of all body systems, taking into account the dosed intake of prescribed drugs and the conditions of comfortable (decent) maintenance of patients during the course of treatment according to the method chosen by the doctor.

Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making.

OBJECTIVES: The objective of this study is to cover the ways of solving the problem of understanding the results of two key methods of pharmacoeconomic analysis - budget impact and cost-effectiveness. It is important to note that pharmacoeconomic assessment based on this evidence often has controversial character. The results of one type of analysis can characterize assessed health technology favorably, and the results of other critically. Pharmacoeconomic evidence is often a crucial part of decision-making in healthcare, that's why clear understanding of combination of this two types of analysis is highly in demand. METHODS: Authors propose methodological solution of the stated problem. This model is a useful tool in making unified pharmacoeconomic report based on cost-effectiveness analysis and budget impact analysis results. Use of this model preserves the meaning and significance of each type of pharmacoeconomic analysis. RESULTS: Three-dimensional pharmacoeconomic model proposes full account of both types of pharmacoeconomic analyses during conclusion preparation, the formation of a single consistent pharmacoeconomic conclusion. Though further validation of a tool is needed, presented model can be interesting for the professional community. CONCLUSIONS: The proposed model of combining budget impact and cost-effectiveness analysis can be used by healthcare decision-makers for obtaining reliable and transparent pharmacoeconomic data.